IceCure Medical's ProSense Shows 99% Recurrence-Free Rate
Ticker: ICCM · Form: 6-K · Filed: Jul 25, 2025 · CIK: 1584371
| Field | Detail |
|---|---|
| Company | Icecure Medical Ltd. (ICCM) |
| Form Type | 6-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: medical-device, clinical-data, cryoablation, breast-cancer
TL;DR
IceCure's cryoablation tech shows 99% recurrence-free rate in breast cancer trials.
AI Summary
On July 25, 2025, IceCure Medical Ltd. announced that its ProSense system was featured at the Japanese Breast Cancer Society Conference. Updated clinical data presented showed a 99% recurrence-free rate for breast cancer patients treated with cryoablation.
Why It Matters
This positive clinical data highlights the effectiveness of IceCure's cryoablation technology in treating breast cancer, potentially offering a less invasive and highly successful treatment option for patients.
Risk Assessment
Risk Level: medium — The filing reports positive clinical data, but the actual market impact and adoption of the technology remain to be seen, introducing some uncertainty.
Key Numbers
- 99% — Recurrence-Free Rate (Indicates the high success rate of cryoablation treatment for breast cancer patients in the presented clinical data.)
Key Players & Entities
- IceCure Medical Ltd. (company) — The company issuing the report and featuring its technology.
- ProSense® (product) — The cryoablation system featured at the conference.
- Japanese Breast Cancer Society Conference (event) — The conference where the clinical data was presented.
- July 25, 2025 (date) — The date of the press release and filing.
FAQ
What specific updated clinical data was presented regarding the ProSense® system?
The filing states that updated positive clinical data showed a 99% recurrence-free rate with cryoablation for breast cancer patients.
Where was the ProSense® system featured?
The ProSense® system was featured at the Japanese Breast Cancer Society Conference.
What is the filing form type and date?
This is a Form 6-K filed on July 25, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.
What is the significance of the 'Report No. 4' for July 2025?
This indicates that this is the fourth report filed by IceCure Medical Ltd. for the month of July 2025, likely containing updates or press releases.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 25, 2025 regarding IceCure Medical Ltd. (ICCM).